Stellar International Inc. (CC:YYS) Enters Into Licensing Agreement With Pharmore GmbH For NeoVisc (R) In Germany
10/19/2005 5:08:46 PM
Stellar International Inc. (TSX VENTURE:SLX) (OTCBB:SLRXF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced that it has signed a Licensing Agreement with Ibbenburen, Germany-based Pharmore GmbH for NeoVisc(R) in Germany. NeoVisc is Stellar's proprietary therapy indicated as a replacement or replenishment ("viscosupplement") for synovial fluid in patients suffering from osteoarthritis ("OA").
comments powered by